Home > Oncology > ASCO 2019 > Genitourinary Cancer - Prostate Cancer > Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma

Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma

Presented By
Dr Daniel P. Petrylak, Yale School of Medicine, USA
Conference
ASCO 2019
Trial
EV-201, EV-301
Medical writer: Kara Nyberg, PhD Enfortumab vedotin, a novel antibody-drug conjugate (ADC), demonstrated pronounced activity in patients with advanced urothelial carcinoma who experienced progression after prior treatment with platinum chemotherapy and an immune checkpoint inhibitor. Results from the pivotal phase II EV-201 study conducted in the United States and Japan showed that single-agent enfortumab vedotin yielded an objective response rate (ORR) of 44%, far surpassing the typical ORR of approximately 11% observed with single-agent chemotherapy in the second- and third-line settings (Abstract LBA4505). Objective responses to enfortumab vedotin were seen in all patient subgroups evaluated (range, 33% to 60%), even those with poor prognostic features indicative of aggressive disease. Most notably, strong responses emerged regardless of whether patients did or did not have liver metastases (38% and 48%, respectively) and whether they did or did not resp...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on